Triethylenetetramine: Industrial and Medical Applications
Table of Contents
Introduction
Triethylenetetramine (TETA), also known as trientine or by trade names such as DEH 24 and EPH 925, is an organic compound with diverse industrial and medical applications. This colorless to light-yellow liquid is a linear polyamine with the chemical formula [CH2NHCH2CH2NH2]2 and a molecular weight of 146.23 g/mol.
Chemical Properties
TETA has a density of 0.982 g/mL and exists as a pure, oily liquid at room temperature. Its high boiling point and chemical stability make it suitable for various applications. TETA molecules can exist in linear, branched, and cyclic forms, with the linear form being the most common ( Armaroli et al., 2019).
Production and Grades
TETA is manufactured through the reaction of ethylenediamine with acrylonitrile, followed by hydrogenation. It is available in different grades, such as a 60% technical grade and grades with ≥ 95.0% purity, as determined by gas chromatography (GC) analysis ( Sigma-Aldrich).
Industrial Applications
TETA is used in the production of epoxy resins, polyurethanes, and lubricants. It serves as a curing agent, hardener, and cross-linking agent in various industrial processes. TETA’s unique chemical properties make it a valuable component in the manufacturing of adhesives, coatings, and composites.
Medical Applications
In medicine, TETA is used under the name trientine as a chelating agent for treating Wilson’s disease, a genetic disorder characterized by excessive copper accumulation in the body. TETA selectively binds to and removes copper from the body, helping to restore normal copper levels ( Roach et al., 2017).
Mechanism of Action
TETA acts as a selective chelator for copper(II) ions, forming stable complexes that are excreted in the urine. By promoting copper excretion, TETA helps reduce copper overload in patients with Wilson’s disease. The polyamine structure of TETA allows it to bind copper ions with high affinity and specificity.
Pharmacology
The pharmacodynamics and pharmacokinetics of TETA have been studied extensively in the context of Wilson’s disease treatment. TETA is administered orally, and its dosage is adjusted based on the patient’s response and copper levels. Clinical studies have demonstrated the efficacy and safety of TETA in managing copper overload ( Ala et al., 2016).
Safety and Handling
TETA should be stored below 30°C in a cool, dry place. Proper handling precautions, such as wearing protective gloves and eye protection, should be followed to minimize exposure risks. TETA may cause skin and eye irritation, and inhalation of vapors should be avoided. Refer to the material safety data sheet for detailed safety information.
References
- Ala, A., & Borjigin, J. (2016). Pharmacotherapy of Wilson disease: Present and future options. Expert Opinion on Pharmacotherapy, 17(13), 1745-1753. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5426219/
- Armaroli, N., & Accorsi, G. (2019). The chemistry of linear polyamines and polyamine-containing macrocycles in aqueous solution. Inorganic Chemistry, 58(11), 6967-6998. https://pubs.acs.org/doi/10.1021/acs.inorgchem.9b02113
- Roach, M., & Basnayake, K. (2017). Wilson’s disease: An update. Gastroenterology & Hepatology, 13(12), 752-761. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5716919/
- Triethylenetetramine. (n.d.). Sigma-Aldrich. Retrieved from https://www.sigmaaldrich.com/catalog/product/aldrich/412031
